For MDS patients, mutations in CBL, IDH2, DNMT3A, TP53 or ASXL1, individually, are associated with shorter survival, with a 3‐year survival rate of only 27% for MDS/MPN patients characterized by having activating mutations of CBL.29, 30 Thus, novel treatment strategies that can be readily implemented in the clinic are needed. This evidence concerns the gene DNMT3A and myeloproliferative neoplasm.